Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Fineline Cube Jun 16, 2026
Company Deals

Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution

Fineline Cube Jun 16, 2026
Company Deals

Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders

Fineline Cube Jun 16, 2026
Policy / Regulatory

China’s NHSA Receives Record 818 Drug Applications for 2026 National Reimbursement Drug List Adjustment

Fineline Cube Jun 15, 2026
Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Fineline Cube Jun 16, 2026
Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Fineline Cube Jun 16, 2026
Company Deals

Sinovac Biotech Directors Reject Alternative Liquidity’s Lowball Tender Offer

Fineline Cube Sep 6, 2023

China-based Sinovac Biotech Ltd. (NASDAQ: SVA) announced that its Board of Directors has unanimously determined...

Company Deals

Abbott to Acquire Insulin Management Firm Bigfoot Biomedical

Fineline Cube Sep 6, 2023

Healthcare giant Abbott (NYSE: ABT) has announced an agreement to purchase Bigfoot Biomedical, a company...

Policy / Regulatory

Taizhou Port Designated as Drug Import Port by NMPA and General Administration of Customs

Fineline Cube Sep 6, 2023

The National Medical Products Administration (NMPA) and the General Administration of Customs have released a...

Company

Sandoz Reports H1 2023 Financials with 8% YOY Growth, Separation from Novartis Looms

Fineline Cube Sep 6, 2023

Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the first half of 2023,...

Policy / Regulatory

Li Li Appointed as New Director of NMPA

Fineline Cube Sep 6, 2023

The State Council has released an announcement regarding appointments and dismissals within the government. Among...

Policy / Regulatory

NHSA Mandates National Standards for Medical Consumables in Basic Medical Insurance

Fineline Cube Sep 6, 2023

The National Healthcare Security Administration (NHSA) has released a notification with a focus on enhancing...

Company Deals

Bristol-Myers Squibb Acquires Rights to Zenas BioPharma’s Obexelimab for Autoimmune Diseases

Fineline Cube Sep 6, 2023

US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a licensing and cooperation...

Company Drug

Neurophth Biotechnology’s NFS-05 Gene Therapy Gets Australian Clinical Trial Approval for ADOA

Fineline Cube Sep 6, 2023

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced that it has received clinical trial...

Company Deals

MGI Tech Partners with Eight Companies to Expand G99-Based Sequencing Applications

Fineline Cube Sep 6, 2023

China-based MGI Tech, a subsidiary of BGI Group (SHE: 300676), has entered into cooperation agreements...

Company Drug

Harbin Gloria Pharmaceuticals’ Zimberelimab Receives NMPA Approval for Cervical Cancer Treatment

Fineline Cube Sep 6, 2023

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has announced that it has received market...

Company

Janssen Appoints Cherry Huang as President of Xi’an Janssen in China Management Shake-Up

Fineline Cube Sep 6, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced a significant management...

Company Drug

Seagen and Genmab Announce Positive Phase III Results for Tivdak in Cervical Cancer

Fineline Cube Sep 5, 2023

Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), and...

Company Drug

SinoMab BioScience’s Suciraslimab Files for Market Approval in China for Rheumatoid Arthritis

Fineline Cube Sep 5, 2023

Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that a market approval...

Company

Weight-Loss Drug Demand Pushes Novo Nordisk to Peak European Market Capitalization

Fineline Cube Sep 5, 2023

Denmark-headquartered pharmaceutical giant Novo Nordisk (NYSE: NVO) achieved a significant milestone last week when it...

Company Legal / IP

Janssen Sues Distributors Over Counterfeit Antiretroviral Therapies in the US

Fineline Cube Sep 5, 2023

Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, filed a lawsuit last week against pharmaceutical...

Company Drug

Columbia University Study Weighs Cost-Effectiveness of Weight-Loss Treatments for Adolescents

Fineline Cube Sep 5, 2023

Researchers at US Columbia University have published the results of a study estimating the cost-effectiveness...

Company

Shanghai Pharmaceuticals Executives Under Investigation for Serious Disciplinary Violations

Fineline Cube Sep 5, 2023

China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has disclosed that several...

Company Drug

BDgene Technology Announces Clinical Milestone for CRISPR-Cas9 Gene Therapy in HSK

Fineline Cube Sep 5, 2023

Gene therapy specialist Shanghai BDgene Technology Co., Ltd has announced the conclusion of three clinical...

Company

Sanofi Announces Management Restructuring with New Leadership Roles in China

Fineline Cube Sep 5, 2023

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced a significant restructuring of its management structure...

Company Deals

ImmuneOnco Biopharmaceuticals Begins Trading on HKEX with Successful IPO

Fineline Cube Sep 5, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) marked its debut on the Hong Kong Stock...

Posts pagination

1 … 496 497 498 … 684

Recent updates

  • Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets
  • Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor
  • Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction
  • Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways
  • Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Company Drug

Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.